SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-18830"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-18830" > Comparison of Effic...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003639naa a2200385 4500
001oai:DiVA.org:liu-18830
003SwePub
008090605s2009 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-188302 URI
0247 a https://doi.org/10.1016/j.amjcard.2008.10.0292 DOI
040 a (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Tikkanen, M.J.u Helsinki University Central Hospital4 aut
2451 0a Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged less than65 Versus =65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)
264 1b Elsevier BV,c 2009
338 a print2 rdacarrier
520 a The efficacy and safety of atorvastatin (80 mg/day) versus simvastatin (20 to 40 mg/day) in older (age =65 years) versus younger (less than65 years) patients were assessed in a prespecified secondary analysis of the 8,888 patients with myocardial infarction in the IDEAL trial, a randomized open-label study. Several cardiovascular end points were evaluated, including the occurrence of a first major coronary event (MCE; nonfatal myocardial infarction, coronary heart disease death, or resuscitated cardiac arrest), the primary end point of the trial, and occurrence of any cardiovascular event (MCE, stroke, revascularization, unstable angina, congestive heart failure, and peripheral artery disease). Although there were no significant interactions between age and treatment, the magnitude of effect in favor of atorvastatin was higher in younger versus older patients (occurrence of first MCE, hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.66 to 0.98; and HR 0.95, 95% CI 0.80 to 1.15, respectively; occurrence of any cardiovascular (CV) event, HR 0.80, 95% CI 0.71 to 0.89; and HR 0.88, 95% CI 0.79 to 0.99, respectively). These results were likely influenced by adherence, which was lower in older patients and those receiving atorvastatin compared with those receiving simvastatin. Rates of any reported serious adverse event were higher in older patients, but did not differ between the 2 statin groups. In conclusion, except for any CV events in the older group, significant reductions in primary and secondary end points were observed only in patients less than65 years of age. The safety of atorvastatin (80 mg) and simvastatin (20 to 40 mg) was similar in patients aged less than65 and greater than65 years with stable coronary disease.
653 a MEDICINE
653 a MEDICIN
7001 a Holme, I.u Ullevål University Hospital4 aut
7001 a Cater, N.B.u Pfizer Inc4 aut
7001 a Szarek, M.u Pfizer Inc4 aut
7001 a Faergeman, O.u Århus University Hospital4 aut
7001 a Kastelein, J.J.P.u Academic Hospital Amsterdam4 aut
7001 a Olsson, Andersu Östergötlands Läns Landsting,Linköpings universitet,Internmedicin,Hälsouniversitetet,Endokrin- och magtarmmedicinska kliniken US4 aut0 (Swepub:liu)andol21
7001 a Larsen, M.L.u Århus University Hospital4 aut
7001 a Lindahl, C.u Pfizer Sweden4 aut
7001 a Pedersen, T.R.u Ullevål University Hospital4 aut
7102 a Helsinki University Central Hospitalb Ullevål University Hospital4 org
7730 t American Journal of Cardiologyd : Elsevier BVg 103:5, s. 577-582q 103:5<577-582x 0002-9149
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-18830
8564 8u https://doi.org/10.1016/j.amjcard.2008.10.029

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy